Dark

Check out our API

AKRO
Akero Therapeutics, Inc. Common Stock
stock NASDAQ

Market Open

Jul 14, 2025 11:22:40 AM EDT

53.05USD+2.870%(+1.48)214,560

52.98Bid 53.10Ask 0.12Spread

Pre-market

0.00USD-100.000%(-51.57)0

After-hours

Jul 11, 2025 4:00:30 PM EDT

51.57USD+0.049%(+0.03)0

OverviewOptionsHistoricalExchangesShortsTrends

AKRO Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

AKRO Specific Mentions

As of Jul 14, 2025 11:22:45 AM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

13 days ago • u/WallstS • r/StockMarket • why_mash_is_not_easy • Discussion • B

Why #MASH is not easy ?
Boehringer Ingelheim terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance back in March, ending an $870 million license agreement inked with Yuhan Corp. for dual GLP-1/FGF21 agonist, BI-3006337 (YH-25724)
$ALT Altimmune’s GLP-1/Glucagon
MASH candidate ‘Pemvidutide’ Ph2 data does not appear to have significant therapeutic benefits on fibrosis associated with MASH
$AKRO Though the ‘Efruxifermin’ Ph2 F4 MASH trial data showed significant results for 96 weeks, the study only randomized 182 patients which is literally a very small population. $MDGL has been working on same F4 trial with 700 patients
$VKTX Viking’s MASH candidate VK2809 Ph2 trial is completed back in Q2 2024, but no further progress has been reported by the company
$LLY Eli Lilly’s ‘tirzepatide’
Ph2 SYNERGY-NASH trial is completed back in Q2 2024, but no further updates have been provided by the company
Post Madrigal’s $MDGL Rezdiffra’s FDA approval back in March 2024, many companies are rethinking MASH strategy
$XBI #MASH #GLP1 #RareDisease

sentiment -0.44

13 days ago • u/WallstS • r/StockMarket • why_mash_is_not_easy • Discussion • B

Why #MASH is not easy ?
Boehringer Ingelheim terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance back in March, ending an $870 million license agreement inked with Yuhan Corp. for dual GLP-1/FGF21 agonist, BI-3006337 (YH-25724)
$ALT Altimmune’s GLP-1/Glucagon
MASH candidate ‘Pemvidutide’ Ph2 data does not appear to have significant therapeutic benefits on fibrosis associated with MASH
$AKRO Though the ‘Efruxifermin’ Ph2 F4 MASH trial data showed significant results for 96 weeks, the study only randomized 182 patients which is literally a very small population. $MDGL has been working on same F4 trial with 700 patients
$VKTX Viking’s MASH candidate VK2809 Ph2 trial is completed back in Q2 2024, but no further progress has been reported by the company
$LLY Eli Lilly’s ‘tirzepatide’
Ph2 SYNERGY-NASH trial is completed back in Q2 2024, but no further updates have been provided by the company
Post Madrigal’s $MDGL Rezdiffra’s FDA approval back in March 2024, many companies are rethinking MASH strategy
$XBI #MASH #GLP1 #RareDisease

sentiment -0.44

Share